Sexe, n (%)
Male
|
62 (53%)
|
Median age, years (range) |
52 (17 – 83) |
Age, n (%)
≥ 70 years
|
13 (11%)
|
Performance status, n (%)
0-1
≥ 2
|
89 (75%)
29 (25%)
|
Body Mass Index, n (%)
< 25
≥ 25
|
64 (54%)
54 (46%)
|
Primitive, n (%)
Soft tissue sarcoma
Bone sarcoma
|
95 (81%)
23 (19%)
|
Subtypes, n (%)
Leiomyosarcoma
Synovial sarcoma
Malignant solitary fibrous tumour
Epithelioid and clear cell sarcoma
Myxofibrosarcoma
Undifferentiated pleomorphic and fusiform cell sarcoma
Others*
|
28 (30%)
14 (15%)
12 (13%)
8 (9%)
7 (8%)
6 (6%)
13 (13%)
|
Site of primitive tumour, n (%)
Lower member
Upper member
Trunk (thorax, abdomen, head and neck)
Uterus
|
43 (45%)
11 (11%)
30 (32%)
11 (11%)
|
Histological grade, n (%)
1
2
3
Not concerned**
|
4 (4%)
27 (29%)
40 (42%)
24 (25%)
|
Pazopanib metastatic line, n (%)
First
Second
≥ Third
|
31 (26%)
44 (37%)
43 (37%)
|
Initial daily dose of pazopanib, n (%)
200 mg
400 mg
600 mg
800 mg
|
2 (2%)
17 (14%)
30 (25%)
69 (59%)
|
Albumin, n (%)
< 35
≥ 35
|
17 (14%)
101 (86%)
|
SGOT - SGPT, n (%)
≤ ULN (≤ 40)
> ULN (> 40)
|
97 (82%)
21 (18%)
|
C Reactive Protein, n (%)
< 10
≥ 10
NA
|
72 (61%)
43 (37%)
3 (2%)
|
Neutrophils/Lymphocytes Ratio (NLR)
< 3.5
≥ 3.5
|
70 (59%)
48 (41%)
|